Novo Nordisk – Growth Continues At Pace

0
Novo Nordisk – Growth Continues At Pace

Excluding the impact of currency changes, Novo Nordisk A/S (NYSE:NVO)’s sales during the first nine months of the year rose 13% to 102.5bn Danish Kroner (DKK). This was driven by strong growth in GLP-1 treatments while Biopharm sales saw a modest uptick.

Get The Full Henry Singleton Series in PDF

Get the entire 4-part series on Henry Singleton in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues

Q3 2021 hedge fund letters, conferences and more

The Man Behind TCI: One Of The World’s Top-Performing Hedge Funds

TCI David Marcus Investment ResearchThe Children's Investment Fund Management LLP is a London-based hedge fund firm better known by its acronym TCI. Founded by Sir Chris Hohn in 2003, the fund has a global mandate and supports the Children's Investment Fund Foundation (CIFF). Q3 2021 hedge fund letters, conferences and more The CIFF was established in 2002 by Hohn Read More

Operating profit for the period rose 12% to DKK 45bn.

The group announced plans to expand its buyback programme by DKK 2bn to DKK 20bn and expects underlying full year sales and operating profit growth between 12% and 15%

The shares rose 1.6% following the announcement

Novo Nordisk GLP-1 Sales

Laura Hoy Equity Analyst at Hargreaves Lansdown:

“Novo’s firing on all cylinders as sales of its Diabetes and Obesity treatments picked up speed. The rollout of Wegovy in the US helped North American Obesity sales nearly double and cemented the group’s position as the leader in obesity prescription drugs. Strong growth among GLP-1 drugs was also encouraging, bringing the group a step closer to its goal of serving a third of the global diabetes market.

Strong growth meant the group is able to throw another DKK2bn back to shareholders via buybacks and maintain its rosy revenue and profit growth figures, reaffirming our view that Novo is a strong player in a growing part of the Pharmaceutical space.

The only shadow of doubt came from Novo’s Insulin sales, which struggled against volume and price declines in the US. This could be a long-term problem with insulin pricing under pressure in the US, but has been more than offset by growth in other areas of the business.“


About Hargreaves Lansdown

Over 1.67 million clients trust us with £138.0 billion (as at 30 September 2021), making us the UK’s number one platform for private investors. More than 98% of client activity is done through our digital channels and over 600,000 access our mobile app each month.

Updated on

Jacob Wolinsky is the founder of ValueWalk.com, a popular value investing and hedge fund focused investment website. Jacob worked as an equity analyst first at a micro-cap focused private equity firm, followed by a stint at a smid cap focused research shop. Jacob lives with his wife and four kids in Passaic NJ. - Email: jacob(at)valuewalk.com - Twitter username: JacobWolinsky - Full Disclosure: I do not purchase any equities anymore to avoid even the appearance of a conflict of interest and because at times I may receive grey areas of insider information. I have a few existing holdings from years ago, but I have sold off most of the equities and now only purchase mutual funds and some ETFs. I also own a few grams of Gold and Silver
Previous article Crude Eyeing OPEC+ Meeting – Where is Oil Headed?
Next article The Keys To A Successful Risk Management Strategy

No posts to display